EUCTR2011-002821-24-IT
Active, not recruiting
Not Applicable
Prospective pharmacodynamic study on patients with moderate, active Crohn’s disease treated with Rifaximin-EIR 400 mg tablets. - RETIC-PD/006/2011
ALFA WASSERMA0 sitesFebruary 27, 2012
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- ALFA WASSERMA
- Status
- Active, not recruiting
- Last Updated
- 13 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •The study will include patients with active, moderate Crohn’s disease defined by a CDAI score of \= 220 and \= 400, localised in the ileocolon or colon (documented either radiologically or endoscopically at least 3 months before inclusion in the study).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1\.2 Adults (18\-64 years) yes
- •F.1\.2\.1 Number of subjects for this age range 22
- •F.1\.3 Elderly (\>\=65 years) yes
- •F.1\.3\.1 Number of subjects for this age range 2
Exclusion Criteria
- •Patients with symptoms attributed to Short Bowel Syndrome, patients potentially requiring immediate surgery for CD will be not included into the study.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
A study to evaluate the pharmacokinetic and pharmacodynamic equivalence of HSP-130 and United States-approved Neulasta (Registered Trademark) and European Union-approved Neulasta (Registered Trademark) administered as a single subcutaneous dose to healthy volunteers.The study will be conducted in healthy subjects. Neulasta is indicated for the treatment of cancer chemotherapy-induced neutropenia.Cancer - Any cancerACTRN12615001049561Hospira, Inc.150
Not yet recruiting
Not Applicable
Study comparing anti-tuberculosis drug levels in saliva, plasma, and urine in patientsACTRN12623001088639Western Sydney Local Health District30
Not yet recruiting
Phase 1
Effect of Jianpi Qushi Recipe on hyperuricemia patients and the serum levels of inflammatory cytokineshyperuricemia patientsITMCTR2200005783Department of Immunity,the Tianjin FirstHospital,Tianjin,
Completed
Not Applicable
Study of two different formulations of finasteride in male volunteers with androgenetic alopeciaAndrogenetic alopeciaSkin and Connective Tissue DiseasesAndrogenic alopeciaISRCTN98903916Polichem S.A. (Switzerland)18
Not yet recruiting
Not Applicable
Investigating the effect of imagery rescripting with and without medication on the symptoms of borderline personality disorderIRCT20240610062067N1Zahedan University of Medical Sciences32